HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and maintained a $23 price target.
June 20, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and keeps $23 price target.
The reaffirmed Buy rating and maintained price target by HC Wainwright & Co. analyst Robert Burns indicates a positive outlook for Allogene Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100